Kevin Lalande, MBA, is a Co-Founder and Managing Director of Santé Ventures, a healthcare and life science venture capital firm founded in 2006 which currently manages $500 million across three funds with 30+ portfolio company investments.
Over the last decade, the partners of Santé Ventures have helped create, build, and finance a valuable portfolio of innovative new venture-backed healthcare companies including LDR Medical (Nasdaq: LDRH, later acquired by ZimmerBiomet), Explorys (acquired by IBM Corp), AbVitro (acquired by Nasdaq: JUNO), Molecular Templates (Nasdaq:MTEM), Millipede Medical (acquired by Boston Scientific), TVA Medical (acquired by Becton Dickinson), and Claret Medical (acquired by Boston Scientific).
Kevin is also the Founder and Chief Investment Officer of Santé Capital, a systematic machine learning hedge fund that began trading capital in 2015 after three years of research and development. Kevin conceived the investment strategy, designed the original MindRank algorithms, and assembled a seasoned team to help drive this related line of business.
Before Santé Ventures and Santé Capital, Kevin spent seven years as an investment professional with Austin Ventures, a prominent venture capital firm with $4B under management. Prior to Austin Ventures, he was a management consultant with McKinsey & Company. Before McKinsey, he founded, built and sold three internet-based companies in the 1990’s. Kevin received a BS in Electrical & Computer Engineering with Honors in 1996 and an MBA with highest distinction from the Harvard Business School in 2001, where he was both a Baker Scholar and a Siebel Scholar.
Mr. Lalande joined the Lumos Pharma Board in 2014.